Search for: [Abstract = "The aim of my dissertation was to conduct the retrospective assessment of choroidal melanoma regression in patients treated with brachytherapy and the comparison of local, distant and functional results of the treatment with the application of Ru\-106 and I\-125 isotopes.376 patients aged 14 to 102, including 195 female and 181 male individuals, who suffered from choroidal and ciliary body melanoma were the subject of study. The patients were treated in the Clinical Unit of the Department of Ophthalmology and Ocular Oncology in the Jagiellonian University Hospital in Krakow between 1995 and 2005. Brachytherapy, a method allowing both conservative and organ\-sparing treatment of the eyeball tumour, was instituted in all the patients. Ruthenium brachytherapy was performed in 171 individuals and iodine brachytherapy was administered in 205 subjects.The ophthalmological examinations included\: assessing distant and near vision acuity, measuring intraocular pressure, examining the anterior part and the fundus of the eye, performing eyeball ultrasonography in A and B presentation and, in some cases, accessory tests.In clinical assessment of melanoma, the following parameters were taken into account\: tumour size, shape, pigmentation, location, and in case of enucleation, the histopathological type. Medium\-sized tumours were detected in 247 patients \(65.7%\), large tumours were found in 71 patients \(18.9%\) and small tumours were present in 58 patients \(15.4%\). In 280 patients \(74.5%\) melanoma tumours were found to be dome\-shaped, in 80 subjects \(21.3%\) they were mushroom\-shaped, and in 8 individuals \(2.1%\) the shape was flat. Medium\-pigmented tumours were present in 237 patients \(63%\) while intensive and amelanotic melanomas were found in 52 \(13.8%\) and 72 \(19.1%\) patients, respectively.Tumour regression rate \(in mm\/year\) was determined for each patient on the basis of the alterations in tumour height. Further, each patient was assigned to one of the following treatment response models\: model I\: tumour height reduction of > 2 mm\/year, model II\: height reduction of 2 \- 0.5 mm\/year, model III\: height reduction of < 0.5 mm\/year.Statistical analysis revealed that the type\/model of treatment response depended on the type of the applied brachytherapy. II model \(53.8%\) prevailed in the group of patients treated with Ru\-106 isotope. In the group of patients treated with I\-125 brachytherapy most tumours \(81%\) showed quick response to the treatment \(model I\). The treatment response model was found to be dependent also on the tumour size, relapse and metastases occurrence, secondary enucleation and the histopathological type. Statistically, the type of the applied isotope was more significant than the tumour size as regards the treatment response rate.The assessment of the correlation between the degree of tumour height regression and the applied treatment revealed that the tumours treated with Ru\-106 isotope showed lower regression range \(47.5% lower after 3 years\) and were stable at greater initial height \(52.5%\) than the tumours treated with I\-125 isotope. In the latter group the height reduction was more considerable \(67.3%\) and"]

Number of results: 0